Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation/randomised phase 2a trial

PURPOSE: Radium 223 dichloride (radium-223) is an alpha particle–emitting bone-directed therapy that prolongs overall survival in men with bone-predominant metastatic castration-resistant prostate cancer (mCRPC). Docetaxel is an antimicrotubule cytotoxic agent that improves survival in mCRPC. We inv...

Descripción completa

Detalles Bibliográficos
Autores principales: Morris, Michael J., Loriot, Yohann, Sweeney, Christopher J., Fizazi, Karim, Ryan, Charles J., Shevrin, Daniel H., Antonarakis, Emmanuel S., Pandit-Taskar, Neeta, Deandreis, Désirée, Jacene, Heather A., Vesselle, Hubert, Petrenciuc, Oana, Lu, Cindy, Carrasquillo, Jorge A., Higano, Celestia S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474951/
https://www.ncbi.nlm.nih.gov/pubmed/31082669
http://dx.doi.org/10.1016/j.ejca.2019.04.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7474951/
https://www.ncbi.nlm.nih.gov/pubmed/31082669
http://dx.doi.org/10.1016/j.ejca.2019.04.007

Ejemplares similares